Molecular determinants of outcome to gemcitabine, cisplatin, and nab-paclitaxel in patients with advanced biliary tract cancer
Genomic profiling using next-generation sequencing identified PI3K pathway activation as key molecular determinant that differentiates patient outcomes between GAP and GC treatments in advanced BTC.
Authors
- D. Kim (ORCID: https://orcid.org/0000-0001-8980-2664)
- Ho Kyoung Hwang (ORCID: https://orcid.org/0000-0003-4064-7776)
- Chang Moo Kang
- Hong Jae Chon (ORCID: https://orcid.org/0000-0002-6979-5812)
- Nam Suk Sim
- Jung Hyun Jo (ORCID: https://orcid.org/0000-0002-2641-8873)
- Hye Jin Choi
- Seonjeong Woo
- Sohyun Hwang
- Sung Huhn Kim
- Beodeul Kang
- Woo Jung Lee
- Sangwoo Kim
- Choong-kun Lee
- Seung Soo Hong
- Young Nyun Park
- Chang Gon Kim
- Chang-Il Kwon
- Min Hwan Kim
- Taek Chung
- Jung Sun Kim
Institutions
- Yonsei University (KR)
- Severance Hospital (KR)
- CHA University Bundang Medical Center (KR)
- Gangnam Severance Hospital (KR)
- CHA University (KR)
Publication Details
- Journal
- Clinical and Molecular Hepatology
- Published
- 2025-12-26
- DOI
- https://doi.org/10.3350/cmh.2025.1019
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Research Foundation
- Korea Health Industry Development Institute
- Ministry of Science and ICT, South Korea